EXICURE, INC. Total Contract Liability
EXICURE, INC. (XCUR) had Total Contract Liability of $21.77 million as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Balance Sheet › Liabilities
us-gaap:ContractWithCustomerLiability · last filed 2022-11-14
- 2022-09-30: Contract with Customer, Liability $21.77M.
- 2022-06-30: Contract with Customer, Liability $23.79M.
- 2022-03-31: Contract with Customer, Liability $26.26M.
- 2021-12-31: Contract with Customer, Liability $28.83M.
| Period end | Contract with Customer, Liability |
|---|---|
| 2022-09-30 | $21.77M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $23.79M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $26.26M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $28.83M 10-Q · filed 2022-11-14 |
| 2021-09-30 | $30.94M 10-Q · filed 2021-11-19 |
| 2020-12-31 | $8.34M 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |